Tau Antibodies and Antigens for Alzheimer's Research
In Alzheimer's Disease (AD), Tau proteins form neurofibrillary tangles, a hallmark of AD pathology.
Anti-Tau antibodies target these pathological Tau forms, offering potential diagnostic and therapeutic
applications. They aim to detect Tau levels for diagnosis, inhibit tangle formation, and explore Tau's role
in AD progression.
| Catalog No. | Products Name | Biomarker | Fc/Tag | Products Information |
| GMP-h-p-tau181-Ab | Anti-human p-tau181 monoclonal antibody(mAb) | Phospho-tau181 (p-tau181) | hFc/mFc | Details |
| GMP-h-p-tau217-Ab | Anti-human p-tau217 monoclonal antibody(mAb) | Phospho-tau217 (p-tau217) | hFc/mFc | Details |
| GMP-h-p-tau231-Ab | Anti-human p-tau231 monoclonal antibody(mAb) | Phospho-tau231 (p-tau231) | hFc/mFc | Details |
| GMP-h-p-tau202/205-Ab | Anti-human p-tau202 and 205 monoclonal antibody(mAb) | Phospho-tau202 and 205 (p-tau202 and 205) | hFc/mFc | Details |
| GMP-h-p-tau212/214-Ab | Anti-human p-tau212 and 214 monoclonal antibody(mAb) | Phospho-tau212 and 214 (p-tau212 and 214) | hFc/mFc | Details |
| GMP-h-p-tau413-Ab | Anti-human p-tau413 monoclonal antibody(mAb) | Phospho-tau413 (p-tau413) | hFc/mFc | Details |
| GMP-h-p-tau422-Ab | Anti-human p-tau422 monoclonal antibody(mAb) | Phospho-tau422 (p-tau422) | hFc/mFc | Details |
| GMP-h-Tau-Ab | Anti-human Tau monoclonal antibody(mAb) | tau proteins (Tau) | hFc/mFc | Details |
| GMP-h-p-tau181-Ag | Phospho-tau181 (p-tau181) antigen/antigen (full length) | Phospho-tau181 (p-tau181) | Details | |
| GMP-h-p-tau217-Ag | Phospho-tau217 (p-tau217) antigen/antigen (full length) | Phospho-tau217 (p-tau217) | Details | |
| GMP-h-p-tau231-Ag | Phospho-tau231 (p-tau231) antigen/antigen (full length) | Phospho-tau231 (p-tau231) | Details | |
| GMP-h-p-tau202/205-Ag | Phospho-tau202 and 205 (p-tau202 and 205) antigen | Phospho-tau202 and 205 (p-tau202 and 205) | Details | |
| GMP-h-p-tau212/214-Ag | Phospho-tau212 and 214 (p-tau212 and 214) antigen | Phospho-tau212 and 214 (p-tau212 and 214) | Details | |
| GMP-h-p-tau413-Ag | Phospho-tau413 (p-tau413) antigen | Phospho-tau413 (p-tau413) | Details | |
| GMP-h-p-tau422-Ag | Phospho-tau422 (p-tau422) antigen | Phospho-tau422 (p-tau422) | Details | |
| GMP-h-Tau-Ag | tau proteins (Tau) antigen | tau proteins (Tau) | Details |
Validation of GeneMedi's Tau products
GeneMedi provides high-quality diagnostics-grade p-tau181, p-tau217, p-tau231, p-tau202/205, p-tau212/214, p-tau413, and p-tau422 antibodies and antigens for the rapid test kit of neurodegenerative diseases (specifically Alzheimer's Disease) in various formats, including standard substance, positive control, ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immunoassay (TINIA), immunonephelometry, and POCT. GeneMedi's well-validated p-tau181/Tau, p-tau217/Tau, p-tau231/Tau, p-tau202/205/Tau, p-tau212/214/Tau, p-tau413/Tau, and p-tau422/Tau pairs demonstrate excellent diagnostic performance in blood tests for Alzheimer's Disease.
Figure 1. Validation of GeneMedi's Anti-human p-tau181/p-tau217/p-tau231 antibody
A. GeneMedi's
GMP-h-p-tau181-Ab01 (Anti-human p-tau181 antibody) is validated to detect the
GMP-h-p-tau181-Ag (p-tau181 antigen) in ELISA, EC50 = 25.26ng/ml.
B. GeneMedi's
GMP-h-p-tau217-Ab01 (Anti-human p-tau217 antibody) is validated to detect the
GMP-h-p-tau217-Ag (p-tau217 antigen) in ELISA, EC50 = 25.85ng/ml.
C.
GeneMedi's
GMP-h-p-tau231-Ab01 (Anti-human p-tau231 antibody) is validated to detect the
GMP-h-p-tau231-Ag (p-tau231 antigen) in ELISA. EC50 = 64.34ng/ml.
Understanding Tau
In Alzheimer's Disease (AD), Tau proteins play a critical role in the disease's pathology. Normally, Tau helps stabilize microtubules in neuronal cells. However, in AD, abnormal phosphorylation of Tau proteins leads to the formation of neurofibrillary tangles (NFTs) inside neurons, disrupting cell function and contributing to neurodegeneration.
Tau Antigen in AD:
In the context of AD, the Tau antigen refers to the Tau protein itself, particularly its hyperphosphorylated forms found in neurofibrillary tangles. These modified Tau proteins are considered biomarkers for AD, correlating with disease progression and severity. Research into Tau's structure and function in AD has significantly advanced our understanding of the disease and has led to the development of diagnostic methods and potential therapeutic targets.
Anti-Tau Antibodies for AD:
Anti-Tau antibodies are designed to recognize and bind to specific epitopes on Tau proteins. In AD research and treatment, these antibodies have multiple applications:
-
Diagnostic Tools: Anti-Tau antibodies are used in assays to detect elevated levels of Tau proteins in cerebrospinal fluid (CSF) or blood, aiding in the diagnosis of AD and monitoring disease progression.
-
Therapeutic Agents: Several anti-Tau antibodies are being investigated as potential treatments for AD. The rationale is that these antibodies could bind to pathological forms of Tau, preventing or slowing the formation of neurofibrillary tangles, and potentially stopping or reversing neuronal damage. Clinical trials are ongoing to assess the efficacy and safety of these antibodies in AD patients.
-
Research Applications: In the lab, anti-Tau antibodies are invaluable tools for studying the role of Tau in AD pathology, including the mechanisms of Tau aggregation and its effects on neuronal function and survival.
The development of Tau-targeted therapies, including anti-Tau antibodies, represents a promising avenue for Alzheimer's research, with the potential to offer new treatment options for patients suffering from this devastating disease.
Facebook
LinkedIn
Twitter
